TONIGHT’S EMAIL IS ALSO SPONSORED BY POLARTECHNICS, an Australian based BioTechnology Company whose niche product MediScan Kestrel has achieved higher than forecasted growth, being ahead of forecast sales by 17% in the 2008 calender year to date.
MediScan Kestrel is on track to exceed sales of over 1 million dollars for this calendar year. Sales revenue is generated by a combination of new system sales together with ongoing network service fees.
Polartechnics developed MediScan Kestrel as a clinical data management tool to support the operation of its TruScreen cervical cancer-screening probe at point of care. Over the last few years MediScan Kestrel has emerged as a leading clinical data and image management system in women’s health clinics in the United Kingdom and Irish hospitals.
If you are interested to learn more of Polartechnics and MediScan Kestrel growth, click here: http://www.polartechnics.com.au/IRM/Content/Index.htm
PLT Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)